Outlook Therapeutics Inc - Understand $otlk stock

$OTLK Market Cap: $140.3 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$94.05M

TTM

Current Assets

$45.62M

Q2 2024

Current Liabilities

$42.55M

Q2 2024

Current Ratio

107.2%

Q2 2024

Total Assets

$47.09M

Q2 2024

Total Liabilities

$130.8M

Q2 2024

Book Value

-$83.67M

Q2 2024

Cash

$32.02M

Q2 2024

P/E

-1.492

Sep 18, 2024 EST

Free Cash Flow

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$0.00	$0.00	$0.00	$0.00	$8.150M	$3.090M	$3.810M	$2.980M	$5.220M	$9.050M
YoY Change				-100.0%	163.75%	-18.9%	27.85%	-42.91%	-42.32%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$0.00	$0.00	$0.00	$0.00	$8.150M	$3.090M	$3.810M	$2.980M	$5.220M	$9.050M
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Selling, General & Admin	$26.67M	$20.74M	$12.77M	$9.970M	$9.370M	$14.23M	$15.88M	$21.56M	$12.91M	$7.320M
YoY Change	28.61%	62.43%	28.07%	6.4%	-34.15%	-10.39%	-26.35%	67.0%	76.37%
% of Gross Profit
Research & Development	$26.45M	$42.33M	$38.96M	$26.34M	$23.81M	$18.50M	$23.81M	$32.76M	$38.88M	$14.12M
YoY Change	-37.51%	8.66%	47.89%	10.63%	28.7%	-22.3%	-27.32%	-15.74%	175.35%
% of Gross Profit
Depreciation & Amortization	$44.19K	$163.6K	$163.6K	$219.4K	$3.360M	$3.050M	$2.690M	$2.390M	$1.820M	$880.0K
YoY Change	-72.99%	0.0%	-25.43%	-93.47%	10.16%	13.38%	12.55%	31.32%	106.82%
% of Gross Profit
Operating Expenses	$26.45M	$42.33M	$51.73M	$36.84M	$33.17M	$32.73M	$39.69M	$54.33M	$51.78M	$21.44M
YoY Change	-37.51%	-18.16%	40.41%	11.07%	1.34%	-17.54%	-26.95%	4.92%	141.51%
Operating Profit	-$53.13M	-$63.07M	-$51.73M	-$36.84M
YoY Change	-15.77%	21.93%	40.41%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Interest Expense	-$1.571M	-$1.536M	-$982.5K	-$1.760M	-$3.470M	-$3.890M	-$5.630M	-$1.850M	-$2.300M	-$900.0K
YoY Change	2.26%	56.34%	-44.18%	-49.28%	-10.8%	-30.91%	204.32%	-19.57%	155.56%
% of Operating Profit
Other Income/Expense, Net	-$3.705M	-$417.0K	-$452.2K	$1.980M	$2.440M	$1.050M	$3.160M	$0.00
YoY Change	788.51%	-7.77%	-122.84%	-18.85%	132.38%	-66.77%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Pretax Income	-$58.98M	-$66.05M	-$53.16M	-$38.51M	-$37.93M	-$33.74M	-$38.35M	-$53.20M	-$48.86M	-$13.29M
YoY Change	-10.7%	24.24%	38.04%	1.53%	12.42%	-12.02%	-27.91%	8.88%	267.64%
Income Tax	$2.800K	$2.800K	$2.000K	-$3.272M	-$3.410M	-$3.650M	$500.0K	$100.0K	-$190.0K	$440.0K
% Of Pretax Income
Net Earnings	-$58.98M	-$66.05M	-$53.16M	-$35.24M	-$34.52M	-$30.09M	-$38.85M	-$53.30M	-$47.39M	-$13.73M
YoY Change	-10.7%	24.24%	50.86%	2.08%	14.72%	-22.55%	-27.11%	12.47%	245.16%
Net Earnings / Revenue					-423.56%	-973.79%	-1019.69%	-1788.59%	-907.85%	-151.71%
Basic Earnings Per Share	-$0.24	-$0.31	-$0.35	-$0.67
Diluted Earnings Per Share	-$0.24	-$0.31	-$0.35	-$0.67	-$1.898M	-$6.103M	-$12.95M	-$24.79M	-$10.48M	-$4.818M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Short-Term Investments	$23.39M	$17.40M	$14.48M	$12.54M	$8.020M	$1.720M	$3.190M	$2.350M	$9.070M	$2.350M
YoY Change	34.46%	20.17%	15.45%	56.36%	366.28%	-46.08%	35.74%	-74.09%	285.96%
Cash & Equivalents	$23.39M
Short-Term Investments
Other Short-Term Assets	$7.587M	$10.12M	$7.031M	$5.410M	$5.490M	$1.590M	$720.0K	$3.330M	$1.790M	$800.0K
YoY Change	-25.05%	43.99%	29.96%	-1.46%	245.28%	120.83%	-78.38%	86.03%	123.75%
Inventory
Prepaid Expenses
Receivables									$20.00K	$0.00
Other Receivables									$4.280M	$0.00
Total Short-Term Assets	$30.98M	$27.52M	$21.51M	$17.94M	$13.50M	$3.300M	$3.900M	$5.680M	$15.16M	$3.150M
YoY Change	12.57%	27.95%	19.89%	32.89%	309.09%	-15.38%	-31.34%	-62.53%	381.27%
Property, Plant & Equipment	$26.17K	$70.36K	$275.1K	$490.0K	$3.180M	$18.49M	$16.09M	$18.66M	$17.76M	$8.010M
YoY Change	-62.81%	-74.42%	-43.87%	-84.59%	-82.8%	14.92%	-13.77%	5.07%	121.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$793.9K	$804.9K	$853.7K	$900.0K
YoY Change	-1.37%	-5.71%	-5.15%
Other Assets	$501.3K	$132.0K	$174.6K	$390.0K	$460.0K	$490.0K	$740.0K	$1.070M	$2.080M	$450.0K
YoY Change	279.72%	-24.38%	-55.23%	-15.22%	-6.12%	-33.78%	-30.84%	-48.56%	362.22%
Total Long-Term Assets	$1.321M	$1.007M	$1.303M	$1.790M	$3.640M	$18.98M	$16.83M	$19.73M	$19.85M	$8.450M
YoY Change	31.18%	-22.71%	-27.19%	-50.82%	-80.82%	12.77%	-14.7%	-0.6%	134.91%
Total Assets	$32.30M	$28.53M	$22.81M	$19.73M	$17.14M	$22.28M	$20.73M	$25.41M	$35.01M	$11.60M
YoY Change
Accounts Payable	$6.575M	$3.491M	$2.196M	$2.390M	$2.280M	$3.610M	$10.95M	$5.070M	$11.56M	$3.100M
YoY Change	88.3%	58.97%	-8.1%	4.82%	-36.84%	-67.03%	115.98%	-56.14%	272.9%
Accrued Expenses	$2.746M	$3.455M	$1.769M	$7.940M	$4.620M	$6.460M	$7.340M	$6.120M	$5.920M	$2.560M
YoY Change	-20.53%	95.35%	-77.73%	71.86%	-28.48%	-11.99%	19.93%	3.38%	131.25%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$6.700M	$13.18M	$0.00	$0.00	$0.00	$0.00
YoY Change				-100.0%	-49.17%
Long-Term Debt Due	$35.56M	$10.93M	$930.7K	$3.690M	$4.830M	$5.200M	$5.010M	$6.180M	$15.82M	$11.48M
YoY Change	225.4%	1074.09%	-74.78%	-23.6%	-7.12%	3.79%	-18.93%	-60.94%	37.8%
Total Short-Term Liabilities	$46.73M	$19.73M	$6.752M	$15.89M	$20.29M	$32.04M	$28.74M	$20.44M	$37.04M	$20.21M
YoY Change	136.86%	192.2%	-57.51%	-21.69%	-36.67%	11.48%	40.61%	-44.82%	83.28%
Long-Term Debt	$0.00	$4.270K	$10.90M	$950.0K	$3.420M	$3.550M	$13.41M	$2.550M	$6.140M	$3.690M
YoY Change	-100.0%	-99.96%	1047.57%	-72.22%	-3.66%	-73.53%	425.88%	-58.47%	66.4%
Other Long-Term Liabilities	$6.220K	$57.14K	$549.9K	$70.00K	$4.200M	$7.500M	$9.310M	$7.590M	$19.38M	$8.150M
YoY Change	-89.11%	-89.61%	685.59%	-98.33%	-44.0%	-19.44%	22.66%	-60.84%	137.79%
Total Long-Term Liabilities	$6.220K	$61.41K	$11.45M	$1.020M	$7.620M	$11.05M	$22.72M	$10.14M	$25.52M	$11.84M
YoY Change	-89.87%	-99.46%	1022.72%	-86.61%	-31.04%	-51.36%	124.06%	-60.27%	115.54%
Total Liabilities	$46.74M	$19.79M	$18.20M	$16.91M	$27.90M	$43.09M	$51.46M	$30.58M	$63.61M	$35.15M
YoY Change	136.16%	8.72%	7.65%	-39.39%	-35.25%	-16.27%	68.28%	-51.93%	80.97%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	250.2M	212.1M	152.7M	72.56M
Diluted Shares Outstanding	250.2M	212.1M	152.7M	72.56M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $140.28 Million

About Outlook Therapeutics Inc

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 24 full-time employees. The company went IPO on 2016-06-13. The firm focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The firm's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The firm sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.

Industry: Biological Products, (No Diagnostic Substances) Peers: 4D Molecular Therapeutics, Inc. Aadi Bioscience Inc AVEO PHARMACEUTICALS, INC. Vaxart Inc Generation Bio Co Poseida Therapeutics Inc Summit Therapeutics Inc Vaxxinity Inc